Diaryl macrocycles as modulators of protein kinases
Jingrong Jean Cui, Princeton, NJ (US); Yishan Li, Princeton, NJ (US); Evan W. Rogers, Princeton, NJ (US); and Dayong Zhai, Princeton, NJ (US)
Assigned to TURNING POINT THERAPEUTICS, INC., Princeton, NJ (US)
Filed by Turning Point Therapeutics, Inc., Princeton, NJ (US)
Filed on Jul. 28, 2023, as Appl. No. 18/227,561.
Application 18/227,561 is a continuation of application No. 17/485,942, filed on Sep. 27, 2021, abandoned.
Application 17/485,942 is a continuation of application No. 16/797,866, filed on Feb. 21, 2020, abandoned.
Application 16/797,866 is a continuation of application No. 16/204,566, filed on Nov. 29, 2018, granted, now 10,618,912, issued on Apr. 14, 2020.
Application 16/204,566 is a continuation of application No. 15/609,962, filed on May 31, 2017, granted, now 10,246,466, issued on Apr. 2, 2019.
Application 15/609,962 is a continuation of application No. 15/113,583, granted, now 9,714,258, issued on Jul. 25, 2017, previously published as PCT/US2015/012597, filed on Jan. 23, 2015.
Claims priority of provisional application 62/106,301, filed on Jan. 22, 2015.
Claims priority of provisional application 62/049,326, filed on Sep. 11, 2014.
Claims priority of provisional application 61/931,506, filed on Jan. 24, 2014.
